

Accepted Manuscript

Title: Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists In Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials

Authors: Majed S. Al Yami PharmD, BCPS, ASH-CHC,
Osamah M. Alfayez PharmD, CDE, Razan Alsheikh PharmD,
BCPS


PII: S1443-9506(18)30134-3
DOI: <https://doi.org/10.1016/j.hlc.2018.03.018>
Reference: HLC 2611

To appear in:

Received date: 15-11-2017
Revised date: 2-3-2018
Accepted date: 14-3-2018

Please cite this article as: Al Yami Majed S, Alfayez Osamah M, Alsheikh Razan. Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists In Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials. *Heart, Lung and Circulation* <https://doi.org/10.1016/j.hlc.2018.03.018>

This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.



Update in Cardiovascular Safety of Glucagon Like Peptide-1 Receptor Agonists In Patients With Type 2 Diabetes. A Mixed Treatment Comparison Meta-Analysis of Randomised Controlled Trials

Majed S. Al Yami, PharmD, BCPS, ASH-CHC^a

Osamah M. Alfayez, PharmD, CDE^{b,c}

Razan Alsheikh, PharmD, BCPS^{b,d}

- a) King Saud bin Abdulaziz University for Health Sciences, Riyadh, Saudi Arabia
- b) Center for Health Outcomes and Pharmacoeconomic Research, University of Arizona, Tucson, AZ, USA
- c) Qassim University, Qassim, Saudi Arabia
- d) King Abdulaziz University, Jeddah, Saudi Arabia

Address correspondence to: **Osamah M. Alfayez**, Center for Health Outcomes and Pharmacoeconomic Research, 1295 N. Martin, P.O. Box 210202, Tucson, AZ 85721-0202. Phone: 520-626-3020. Fax: 520-626-2023. Email: alfayez@pharmacy.arizona.edu

Abstract

The aim of this mixed treatment comparison (MTC) meta-analysis was to determine glucagon like peptide-1 (GLP-1) receptor agonists' effects on cardiovascular (CV) outcomes in patients with type 2 diabetes (T2DM).

Methods: A comprehensive, systematic review was conducted using EMBASE and Medline databases. All included trials were large CV outcome trials of GLP-1 agonists versus placebo in T2DM. The primary outcomes of this MTC meta-analysis were death from CV causes, non-fatal MI, and non-fatal stroke. Hospitalisation for heart failure (HF) was evaluated as a secondary endpoint.

Download English Version:

<https://daneshyari.com/en/article/11019006>

Download Persian Version:

<https://daneshyari.com/article/11019006>

[Daneshyari.com](https://daneshyari.com)